(CercleFinance.com) – The genOway stock gained more than 4% in Paris today, helped by a recommendation from Euroland which today initiated the monitoring of the stock for purchase with a price target of 5.80 euros , representing an upside potential of 41%.
In a research note, the brokerage company welcomes the transformation carried out by the company since 2018, which has notably enabled it to accelerate its growth and improve its margins through an adjustment of its economic model.
‘Long presented as a biotechnology company, genOway is in reality a provider of innovative solutions serving biopharmaceutical companies and their preclinical research’, underlines the market intermediary.
‘Indeed, the company designs and develops genetically modified research models to better predict patients’ response to future treatments,’ continues Euroland.